You are here: Home » Companies » News
Business Standard

Metropolis Healthcare plans to expand footprint

Mulling IPO in 2-3 years

Sohini Das  |  New Delhi 

Metropolis Healthcare, a multi-national chain of diagnostic centers, is planning to expand its India footprint by adding 12 new laboratories and over 75 new collection centers with an investment of close to Rs 70-80 crore. The company is also mulling an initial public offering (IPO) in the next two to three years.

As for the current expansion plan, it would be funded from internal accruals.

Metropolis Healthcare recently opened a laboratory in Ahmedabad, near Asarwa to facilitate faster turnaround time and maximise consumer reach. Metropolis has been present in Ahmedabad under the banner of Sanket Metropolis for more than five years.

With the goal to tap the interior markets of Ahmedabad and its adjoining areas, the lab will now facilitate patients from smaller towns in the interiors to avail quality laboratory testing locally, the company said in a statement. This is Metropolis' seventh company-owned laboratory during the financial year 2012-13. It will cater to a population of around 15 to17 lacs spanning neighbouring areas like Asarwa, Shaibaug, Meghnaninagar, Naroda, Saraspur, Bapunagar and towns like Kalol,Gandhinagar & other small towns.

Commenting on the occasion  Ameera Shah, managing director & CEO, MetropolisHealthcare  said, "The city is growing at a very fast pace and so are the changing needs and demands of its inhabitants."

The company is also looking to add brown-field laboratories in the tier II and tier III cities like Nagpur, Cochin, Amritsar among others. It is looking at acquiring in Rajasthan, Punjab, Uttar Pradesh, Chattisgarh and West Bengal.

 In June 2010, Warburg Pincus, a private equity firm, has invested up to $85 million in Metropolis Healthcare Ltd.

Founded in 1981, Metropolis Healthcare  Sushil Shah now has a network of  85 plus diagnostic centers and 600 plus collection centers across India, Sri Lanka, South Africa and Middle East. It provides around 4500 specialised tests under a single roof ranging from oncology to genetics, molecular biology and immunoassays.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sat, October 06 2012. 17:57 IST